잠시만 기다려 주세요. 로딩중입니다.

Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming

Diabetes & Metabolism Journal 2020년 44권 5호 p.640 ~ 657
소속 상세정보

Abstract


The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although vitamin E, pioglitazone, and liraglutide improved liver histology in randomized trials, there are currently no Food and Drug Administration-approved drugs for NASH. Five pharmacologic agents?obeticholic acid, elafibranor, cenicriviroc, resmetirom, and aramchol?are being evaluated in large, histology-based phase 3 trials. Within 2 to 4 years, new and effective drugs for the treatment of NASH are expected. Additionally, many phase 2 trials are ongoing for various agents. Based on the results of phase 2 and 3 trials, combination treatments are also being investigated. Future treatment strategies will comprise drug combinations and precision medicine based on the different phenotypes of NASH and treatment response of the individual patient.

키워드

Drug therapy; combination; Fibrosis; Non-alcoholic fatty liver disease; Precision medicine; Therapeutics

원문 및 링크아웃 정보

등재저널 정보